Verdict: Side-by-side breakdown using the Bull Rankings model. CVS scored 52.2, PGNY scored 67.0 — PGNY leads.
Compare another set
CVS
CVS Health Corporation
Healthcare Plans · Quality-Growth
52.2
$86.16 · $110.2B
fundamentals as of
Score gap
14.8
PGNY leads
PGNY
Progyny, Inc.
Healthcare Plans · Quality-Growth
67
$27.93 · $2.1B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestCVS22.7x
Fastest growthCVS+7.8%
Strongest balance sheetPGNY0.06
Highest qualityPGNY86 / 100
Largest discount to fair valueCVS-61%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
CVS
stronger →← stronger
PGNY
45
Qualityreturns · margins · balance sheet
86
70
Growthrevenue & earnings expansion
62
45
Valuevaluation vs sector peers
57
PGNY is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
CVS
PGNY
$11.8bA-
FCF
$178mC
+7.8%B
Rev
+5.5%C+
0.96C
D/E
0.06A-
22.7xB+
P/E
30.4xB
0.21A
PEG
2.69C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
CVS
PGNY
61% below
Price vs fair valuelower is cheaper
30% below
~-15%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~-1%/yr
+141%
1-yr DCF upside
+30%
+154%
5-yr DCF upside
+43%
+176%
10-yr DCF upside
+65%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
CVS
No notable signals flagged.
PGNY
Why this score
Buying back stock
Durable high returns
The companies
CVSCVS Health Corporation
Healthcare Plans · $86.16 · beta 0.60
Why now
Healthcare Plans · market cap $110.2b. Down 22% from 52-week high of $110.68 — deep drawdown territory. PEG 0.21 — paying under fair value for the growth rate. 25 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $115.76 (implying +34% upside).
Moat
Free cash flow runs well ahead of reported net income, mostly because of depreciation and amortization ($4.5b) — non-cash charges that hold down reported earnings while cash generation stays strong. $110.2b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Net margin 1.2% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 6% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
PGNYProgyny, Inc.
Healthcare Plans · $27.93 · beta 1.02
Why now
Healthcare Plans · market cap $2.1b. 16% off the 52-week high of $33.06. 12 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $34.42 (implying +23% upside).
Moat
ROE 17% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income, mostly because of stock-based pay ($107m) — a real cost to shareholders, paid in shares rather than cash.
Risk
Trailing P/E 30x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where CVS and PGNY diverge
On the headline score the gap is 14.8 points in favor of PGNY. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
QualityCVS 44.9 · PGNY 86.1PGNY +41.2
ValueCVS 45.1 · PGNY 56.5PGNY +11.4
GrowthCVS 70.3 · PGNY 61.7CVS +8.6
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is PGNY or CVS the better stock?
PGNY scores higher: PGNY 67.0, CVS 52.2 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do PGNY and CVS differ most?
The widest gap is quality, where PGNY leads by 41 points on the 0–100 pillar scale. Neither name sweeps: they trade the lead across the three pillars, so the comparison is a trade-off rather than one being better on every measure.
How are PGNY and CVS scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.